Prolia Treatment - Long term benefits | Osteoporosis | Amgen

OSTEOPOROSIS IS A CHRONIC, PROGRESSIVE CONDITION AND CONTINUED TREATMENT IS ESSENTIAL TO ENSURE LONG-TERM BENEFIT1

Use of a ‘treat-to-target’ strategy can help enhance and individualize the care of patients with chronic diseases including osteoporosis.
Total hip BMD T-scores >-2.5 are associated with a lower incidence of non-vertebral fractures in a study of Prolia®, supporting the concept that a specific T-score can be considered as a practical goal for therapy.2
Improvements in total hip BMD T-score and a sustained low incidence of non-vertebral fractures are observed throughout 10 years of Prolia® treatment.2,3
Analysis and data from FREEDOM study showing expected 1-year non-vertebral fracture incidence vs total hip bone mineral density T-score.
Data are from postmenopausal women enrolled in the FREEDOM study who had an observed total hip BMD T-score at FREEDOM baseline and ≥1 observed total hip BMD T-score during the FREEDOM trial or extension.2
Click here to find out how long you should treat your patients with Prolia® to achieve a certain increase in BMD.

References:
BMD: bone mineral density; CI: confidence interval.
  1. Brown, et al. J Bone Miner Res. 2013;28:746–52.
  2. Ferrari S, et al. Osteoporos Int. 2016;27(Suppl 1): OC17.
  3. Bone HG, et al. Lancet Diabetes Endocrinol. 2017;5:513–23.

SMPC

The information contained in this site is for healthcare professionals only

I am a patient
I am a member of the public